Peripheral arterial Disease LDL-C and cardiovascular Risk significantly lowering with Evolocumab

被引：0
|
作者：
Unger-Hunt, Lydia
机构：
来源：
AUSTRIAN JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM | 2018年 / 11卷 / 02期
关键词：
D O I：
10.1007/s41969-018-0028-5
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：68 / 70
页数：3
相关论文
共 50 条
  • [1] Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States
    Gandra, Shravanthi R.
    Villa, Guillermo
    Fonarow, Gregg C.
    Lothgren, Mickael
    Lindgren, Peter
    Somaratne, Ransi
    van Hout, Ben
    CLINICAL CARDIOLOGY, 2016, 39 (06) : 313 - 320
  • [2] COST-EFFECTIVENESS OF LDL-C LOWERING WITH EVOLOCUMAB IN PATIENTS WITH HIGH CARDIOVASCULAR RISK IN THE UNITED STATES
    Gandra, S. R.
    Villa, G.
    Fonarow, G.
    Lothgren, M.
    Lindgren, P.
    Somaratne, R.
    van Hout, B.
    VALUE IN HEALTH, 2016, 19 (03) : A3 - A3
  • [3] Benefit of LDL-C lowering with evolocumab on cardiovascular outcomes by age & sex: an analysis of the FOURIER trial
    Sever, P. S.
    Gouni-Berthold, I.
    Keech, A.
    Giugliano, R.
    Pedersen, T.
    Wasserman, S.
    Im, K.
    Sabatine, M.
    O'Donoghue, M.
    EUROPEAN HEART JOURNAL, 2018, 39 : 1041 - 1042
  • [4] LDL-C Lowering with Evolocumab and Arterial Aneurysms: Long-Term Analysis from the FOURIER Trial
    Gaba, Prakriti
    Zimerman, Andre
    O'Donoghue, Michelle
    Giugliano, Robert
    Murphy, Sabina
    Kuder, Julia
    Monsalvo, Maria Laura
    Flores-Arredondo, Jose
    Atar, Dan
    Keech, Anthony
    Sabatine, Marc
    Marston, Nicholas
    Bergmark, Brian
    CIRCULATION, 2024, 150
  • [5] LDL-C LOWERING EFFICACY OF EVOLOCUMAB (AMG 145) COULD REDUCE APHERESIS IN PATIENTS AT HIGH RISK FOR CARDIOVASCULAR EVENTS IN GERMANY
    Villa, G.
    Schmid, T.
    Lothgren, M.
    Michailov, G.
    VALUE IN HEALTH, 2014, 17 (07) : A504 - A504
  • [6] IMPORTANCE OF BASELINE LDL-C IN THE ASSOCIATION BETWEEN LDL-C LOWERING AND CARDIOVASCULAR RISK: A META-REGRESSION ANALYSIS
    Hawe, E.
    Meleth, S.
    Wolowacz, S.
    Bilitou, A.
    ATHEROSCLEROSIS, 2022, 355 : E266 - E267
  • [7] LOG LINEAR ASSOCIATION BETWEEN LDL-C LOWERING AND CARDIOVASCULAR RISK REDUCTION
    Jayanna, Manju Bengaluru
    Robinson, Jennifer
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 232 - 232
  • [8] Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease
    Albosta, Michael S.
    Grant, Jelani K.
    Taub, Pam
    Blumenthal, Roger S.
    Martin, Seth S.
    Michos, Erin
    VASCULAR HEALTH AND RISK MANAGEMENT, 2023, 19 : 421 - 431
  • [9] Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States (vol 39, pg 313, 2016)
    Gandra, Shravanthi R.
    CLINICAL CARDIOLOGY, 2016, 39 (10) : 621 - 621
  • [10] Impact of Lowering LDL-C With Evolocumab on Everyday Cognition in Participants From the FOURIER Trial
    Gencer, Baris
    Mach, Francois
    Guo, Jianping
    Im, Kyungah
    Ruzza, Andrea
    Wang, Huei
    Kurtz, Christopher
    Pedersen, Terje R.
    Keech, Anthony C.
    Ott, Brian
    Sabatine, Marc S.
    Giugliano, Robert P.
    CIRCULATION, 2019, 140
12345